Previous work showed that acute myelocytic leukemia blasts accumulate less long chain polyglutamates of methotrexate (MTX) than acute lymphocytic leukemia blasts when incubated with this radiolabeled antifolate. This difference likely explains the increased sensitivity of lymphoid leukemias to short-term exposure of MTX as compared with myeloid leukemias. In this study, we examined the basis for differences between long chain MTX polyglutamate accumulation between different leukemia cell types using both leukemia cell lines and blasts freshly isolated from blood of leukemic patients. The major difference found between leukemia cells that accumulate long chain polyglutamates and those that do not were differences in Km values for the enzyme folylpolyglutamate synthetase. Km values did not change with partial purification of this enzyme, indicating that interfering substances in crude lysates were not responsible for this difference. We postulate that there may be differences in the properties of this enzyme related to tissue specific expression. In contrast to MTX, both Tomudex (Zeneca Pharmaceuticals, Wilmington, DE) and 1843U89, potent inhibitors of thymidylate synthetase, have low Kms for folylpolyglutamate synthetase, and polyglutamate forms of these inhibitors are accumulated to the same degree in both myeloid and lymphoid acute leukemia cells, paralleling the equivalent cytotoxicity found between myeloid and lymphoid leukemia cell lines. Based on these results, we believe a clinical trial of Tomudex in patients with acute myeloid leukemia is warranted.
Previous work showed that acute myelocytic leukemia that interfering substances in crude lysates were not responblasts accumulate less long chain polyglutamates of methosible for this difference. We postulate that there may be trexate (MTX) than acute lymphocytic leukemia blasts when differences in the properties of this enzyme related to tissue incubated with this radiolabeled antifolate. This difference specific expression. In contrast to MTX, both Tomudex (Zenlikely explains the increased sensitivity of lymphoid leukeeca Pharmaceuticals, Wilmington, DE) and 1843U89, potent mias to short-term exposure of MTX as compared with myinhibitors of thymidylate synthetase, have low K m s for folyleloid leukemias. In this study, we examined the basis for polyglutamate synthetase, and polyglutamate forms of differences between long chain MTX polyglutamate accuthese inhibitors are accumulated to the same degree in both mulation between different leukemia cell types using both myeloid and lymphoid acute leukemia cells, paralleling the leukemia cell lines and blasts freshly isolated from blood equivalent cytotoxicity found between myeloid and of leukemic patients. The major difference found between lymphoid leukemia cell lines. Based on these results, we leukemia cells that accumulate long chain polyglutamates believe a clinical trial of Tomudex in patients with acute and those that do not were differences in K m values for the myeloid leukemia is warranted. enzyme folylpolyglutamate synthetase. K m values did not ᭧ 1997 by The American Society of Hematology. change with partial purification of this enzyme, indicating humidified atmosphere in RPMI 1640 media containing 10% fetal
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.